Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone acetonide
- Development stage
- Approved
- Lead developer
- Apothecon
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intranasal, Topical, Ophthalmic, Intraarticular, Oral, Inhalation, Intramuscular, Dental, Intralesional, Rectal
01
Overview
**Triamcinolone acetonide** is a synthetic glucocorticoid corticosteroid, specifically the C16α,17α acetonide derivative of triamcinolone. It acts as an agonist of the glucocorticoid receptor and is approximately five times as potent as cortisol, with minimal mineralocorticoid activity. Its primary mechanism is anti-inflammatory and immunosuppressive action through inhibition of multiple inflammatory cytokines and mediators. Clinically, it is used to treat a wide range of conditions including allergic rhinitis (nasal spray), various skin disorders (topical), macular edema associated with uveitis (ophthalmic injection), arthritis (intra-articular injection), and other inflammatory or autoimmune diseases. It was first approved in 1957 and remains widely used in multiple formulations for both systemic and local administration[2][3][4][5].
- Brand names
- AristocortKenalogNasacortTridermTrianexTriamcotTriacetCinolarDermasorb TA Complete KitPediaderm TATriaderm Mild CreamTriaderm Regular CreamZytopicOracortOraloneTriesenceXipereZilretta
- Other names
- triamcinolone acetonide
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on triamcinolone acetonide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triamcinolone acetonide.